Clinical Trials Logo

Clinical Trial Summary

Glaucoma, a progressive optic disc neuropathy causing visual field reduction, is the second leading cause of world blindness. The treatment of glaucoma is mainly based in reducing intraocular pressure (IOP) with topical medications. Many patients required two or more medications to achieve a target IOP. Combinations of B-blockers and prostaglandin analogs (PGA) are frequently used in clinical practice because their additive effect in lowering IOP levels. The aim of this study was to investigate the effects of fixed combinations of timolol maleate and PGA on the blood-aqueous barrier and evaluate the measurement of foveal thickness in pseudophakic patients with primary open-angle glaucoma (POAG).


Clinical Trial Description

Most studies found a lower incidence of systemic and ocular adverse events with fixed combinations than with the unfixed combinations. Fixed combinations are better tolerated than their respective prostaglandin analogue. However, among the most serious side effects induced by PGA are the breaking down of the blood-aqueous barrier (BAB) and the development of cystoids macular edema (CME). Also, timolol maleate drops increase protein concentration in the human and benzalkonium chloride, eye drops preservative induces anterior chamber inflammation. This randomized, masked-observer, prospective clinical trial was approved by the Ethics Committee of the University of Campinas, and it adhered to the tenets of the Declaration Of Helsinki. Written informed consent was obtained from each patient. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01978015
Study type Interventional
Source University of Campinas, Brazil
Contact
Status Completed
Phase Phase 4
Start date October 2011
Completion date January 2013

See also
  Status Clinical Trial Phase
Completed NCT00508040 - Evaluation of Birdshot Retine Choroidopathy Treatment by Either Steroid or Interferon alpha2a Phase 2
Terminated NCT00114062 - Study to Treat Uveitis Associated Macular Edema Phase 2
Completed NCT03025945 - Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo N/A
Recruiting NCT05158699 - Effectiveness of Periocular Drug Injection in CATaract Surgery Phase 3
Withdrawn NCT02598869 - Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema Phase 4
Terminated NCT04527523 - Descemet Membrane Endothelial Keratoplasty vs. Descemet's Stripping With Endothelial Keratoplasty vs. Descemet Stripping Only
Completed NCT02294656 - Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide Phase 1
Withdrawn NCT00406172 - Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME) Phase 3
Not yet recruiting NCT04856670 - Assessing Diabetes Mellitus on Cytokine Analysis and Macular Edema Following FLACS
Completed NCT02609165 - Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema Phase 2
Withdrawn NCT00438243 - Pilot Study of the Effect of Topical Bromfenac Ophthalmic Solution 0.09%in Patients With Acute Post-operative Cystoid Macular Edema. Phase 2
Completed NCT00464581 - Lucentis for Treatment of Macular Edema N/A
Active, not recruiting NCT03465124 - Evaluation of Central Macular Thickness in Femtosecond Laser-assisted Cataract Surgery N/A
Recruiting NCT02486484 - Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection Phase 2
Completed NCT00790803 - Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema N/A
Recruiting NCT04225611 - Therapeutic Contact Lens Drug Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular Edema Phase 1/Phase 2
Completed NCT05832996 - Cool vs Room-temperature Artificial Tears Phase 4
Completed NCT05615805 - The Effect of Ocular Rinse Volume on Surface Irritation After Intravitreal Injections N/A
Completed NCT00494494 - Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery Phase 4
Terminated NCT00346983 - Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics Phase 1/Phase 2